## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Summary</td>
<td>1</td>
</tr>
<tr>
<td>Glossary</td>
<td>3</td>
</tr>
<tr>
<td>1 Strategic Case</td>
<td>5</td>
</tr>
<tr>
<td>2 Preferred Option</td>
<td>11</td>
</tr>
<tr>
<td>3 Summary</td>
<td>20</td>
</tr>
<tr>
<td>References</td>
<td>21</td>
</tr>
<tr>
<td>Appendix A – Radiation Epidemiology &amp; Radiobiology Strategic Options Diagram</td>
<td>22</td>
</tr>
</tbody>
</table>
Executive Summary

Background

Significant epidemiological and radiobiological research involving nuclear industry workers was previously sponsored by parts of the UK nuclear industry (e.g. British Nuclear Fuels Ltd and United Kingdom Atomic Energy Authority). This work generated important research assets which are now owned by the Nuclear Decommissioning Authority (NDA). NDA has continued to manage these assets and support research in these areas as it has a potential impact on the safety, cost, management, delivery and public acceptability of our decommissioning mission.

The objective of NDA’s Radiation Epidemiology and Radiobiology Research Strategy is to ensure that our assets are appropriately managed and that research relevant to our mission is carried out.

Approach

In October 2013 NDA published a Credible Options paper[1] for managing epidemiology and radiobiology research and associated research assets.

The options for managing our research programme considered were:

- **Option 1**: Close the programme and withdraw from these areas
- **Option 2**: Close the programme but maintain a watching brief for relevant research
- **Option 3**: Compete the programme through open tender with NDA maintaining overall management responsibility
- **Option 4**: Transfer responsibility for management of the programme to one of our SLCs
- **Option 5**: Further develop a strategic relationship with Public Health England (PHE) (formerly the Health Protection Agency (HPA)) with the long-term aim of restructuring the ownership and management of the assets

These options were reviewed against a number of criteria in the Credible Options paper[1] and the results of this initial assessment indicated that Option 5 provided the best fit to the identified requirements.

Following a period of review, which has allowed stakeholders to comment on these options and the initial assessment process, we have concluded that Option 5 - ‘Further develop a strategic relationship with PHE’ is the preferred option to take forward. This strategic relationship could potentially result in combined governance with the transfer of assets (e.g. databases) and funding from NDA to PHE (via their sponsoring Government departments) so as to better reflect the overall NDA strategic objectives.
Way Forward

NDA will further develop its strategic relationship with PHE whilst ensuring that our assets are appropriately managed and that research relevant to our mission is carried out. We will also investigate further the possibility of restructuring the ownership and management of the assets. A key part of this will be to continue to understand the views of stakeholders as we move forward with this strategy. Legal, ethical and financial implications of any restructuring will need to be considered. We will provide regular updates on the implementation of this strategy and provide the opportunity for stakeholders to express their views on any proposed restructuring.

Document Revision Record

<table>
<thead>
<tr>
<th>Version</th>
<th>Stage</th>
<th>Record of Change</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft 0.1</td>
<td>A</td>
<td>N/A</td>
<td>12 June 2013</td>
</tr>
<tr>
<td>Draft 0.2</td>
<td>A</td>
<td>Update following Epidemiology Governance Group</td>
<td>26 June 2013</td>
</tr>
<tr>
<td>Draft 0.3</td>
<td>A</td>
<td>Update following Strategy Development &amp; Implementation Group</td>
<td>20 August 2013</td>
</tr>
<tr>
<td>Issue 1</td>
<td>A</td>
<td>Update following Executive Team Meeting - Strategy &amp; Planning</td>
<td>3 October 2013</td>
</tr>
<tr>
<td>Draft 1.1</td>
<td>B</td>
<td>N/A</td>
<td>27 March 2014</td>
</tr>
<tr>
<td>Draft 1.2</td>
<td>B</td>
<td>Update following internal review</td>
<td>3 July 2014</td>
</tr>
<tr>
<td>Draft 1.3</td>
<td>B</td>
<td>Minor corrections</td>
<td>22 August 2014</td>
</tr>
<tr>
<td>Draft 1.4</td>
<td>B</td>
<td>Update following Strategic Authorities Forum</td>
<td>29 August 2014</td>
</tr>
<tr>
<td>Issue 1</td>
<td>B</td>
<td>Update following Epidemiology Governance Group and comments from Director – Strategy &amp; Technology</td>
<td>11 December 2014</td>
</tr>
</tbody>
</table>
Glossary

BNFL British Nuclear Fuels Ltd.

DH Department of Health

Data Custodian The individual responsible for safeguarding data and assuring appropriate use (not to be confused with Data Owner, Data Controller or Data Processor, as defined under the Data Protection Act)

Epidemiology The study of the patterns, causes, and effects of health and disease outcomes within populations

HPA Health Protection Agency (now part of PHE)

HTA Human Tissue Authority

NDA Nuclear Decommissioning Authority

NRRW National Registry for Radiation Workers

PHE Public Health England (formed on 01 April 2013) is an Executive Agency of the Department of Health and is accountable to the Secretary of State for Health. PHE works with the devolved administrations and is able to co-ordinate nationwide action to tackle threats to health from infectious disease, radiation, chemicals and other health hazards, and to enable effective UK-wide emergency preparedness, resilience and response arrangements. Public Health England’s Centre for Radiation, Chemicals and Environmental Hazards (CRCE) has offices throughout England and in Wales and Scotland.

Radiobiology The study of the action of radiation on biological systems

SLC Site Licence Company
1 Strategic Case

1.1 Topic Background and Context

Radiation epidemiology and radiobiology provide evidence in relation to the possible health risks of exposure to ionising radiation. Such evidence helps to develop areas of knowledge that can have an impact on the safety, cost, management, delivery and public acceptability of decommissioning activities. As outlined in our strategy for Research and Development (R&D)[2], under the Energy Act 2004, NDA is required to promote and, where necessary, carry out research in relation to its prime function of decommissioning and clean-up.

The Radiation Epidemiology and Radiobiology Research Strategy will outline the NDA’s approach to this topic area. The objective of our strategy is to ensure that our assets are appropriately managed and that research relevant to our mission is carried out.

1.1.1 Research

Within this topic there are two distinct areas of research to be considered and for the purposes of this strategy the technical scope of these areas can be defined as follows:

- Radiation Epidemiology - using exposure (primarily radiation dose) and health (primarily cancer registration and cause of death) information collected for a nuclear worker population with statistical analysis to study the patterns, causes, and effects of health and disease outcomes within that population.
- Radiobiology - using biological samples from nuclear workers, with dosimetry information and laboratory techniques, to directly study the action of radiation on biological systems.

The knowledge gained from these areas can have an impact on NDA’s decommissioning mission (e.g. compliance with dose limits - or duty of care to assure compliance with best knowledge - may impact on working practices and/or staffing levels for workers within the decommissioning sector).

1.1.2 Research Assets

The primary asset required for enabling epidemiological research is relevant information stored in a database in a structured manner. Following its formation, NDA assumed ownership of two epidemiological databases via transfer schemes. The databases respectively contain information relating to workers employed at sites operated by the former British Nuclear Fuels Ltd (BNFL) and the former United Kingdom Atomic Energy Authority (UKAEA). These databases contain information on tens of thousands of workers spanning several decades, have taken many million pounds worth of effort to construct and are considered unique, irreplaceable and, in the context of such research, invaluable.
Previous radiobiological research projects have resulted in a collection of biological materials, isolated from blood samples voluntarily donated by nuclear workers employed, at some time, at the Sellafield site. This also now falls within the NDA estate and is a potential asset to further research within this area.

The future of these research assets is a key consideration.

1.1.3 Other Considerations

Because some of this work involves personal/medical information and/or biological samples there are additional legal and ethical issues that must also be considered. In particular, the position of an individual or their representative(s), with regard to (data) asset ownership, irrespective of the ownership of the database, file or sample store in which such information is held, indicates that they too are important stakeholders with respect to any proposed strategy.

Research into the potential health effects of radiation exposure has also been conducted by other national and international bodies and it may be considered that a coordinated UK approach would ensure the most cost-effective use of public funds.

1.2 Current Situation

1.2.1 Pre-2010 Strategy Arrangements

The existing strategy for our radiation epidemiology and radiobiology dates back to our first Strategy\(^3\), which was produced in 2006 shortly after NDA assumed responsibility for oversight of this work. In the first Strategy, a commitment was made to continue to support the collection and management of epidemiological data (including dosimetry) and radiobiological samples, and also that the epidemiological and radiobiological research programmes would continue to be funded as part of our skills strategy.

Arrangements for delivery of the Strategy commitments were through two primary routes. Management of the research assets and the radiation epidemiology and radiobiology research programme for the former BNFL sites was through a contract with Westlakes Scientific Consulting (WSC), an organisation which had extensive previous experience in this role (this work having been outsourced to them by BNFL in 1994). The United Kingdom Atomic Energy Authority was contracted to continue to manage the ‘UKAEA’ epidemiological database and research programme and this was further largely subcontracted to Nuvia Limited, an organisation with staff with extensive relevant experience.

Subsequent events have made this strategy untenable:

- WSC went into administration in July 2010. This put the epidemiological database associated with research on the effects of radiation on the workforce at the former BNFL sites at risk of being lost or irretrievably damaged. Biological samples collected from workers at the former BNFL
sites, for use in genetics research, were also held by WSC and were similarly put at risk.

- Following restructuring of their business, the United Kingdom Atomic Energy Authority informed us, in 2010, that they no longer wished to provide management for the ‘UKAEA’ epidemiological project and database.

1.2.2 2010-2011 Recovery and Options Review

The collapse of WSC forced NDA to take immediate direct action to protect vulnerable research assets and an options review was subsequently undertaken within NDA and in consultation with the former NDA-WSC Epidemiology Governance Group.

NDA is a strategic body and delivers its mission through others, primarily our Site Licence Companies. Direct management of such assets would therefore be outside of our normal methods of operation.

Following a review of the available external options, we identified the Health Protection Agency (HPA) as being the organisation with the most extensive skills, knowledge and experience in radiation epidemiological and radiobiological research involving nuclear workers – particularly through their ownership and management of the National Registry for Radiation Workers (NRRW). The HPA’s national role as the advisory body on radiation protection, their overall expertise and experience within this area and the security of their position as a non-departmental public body also gave increased confidence as to the likely stability of a contractual arrangement with them.

The NDA Governance Group, led by an independent Chair and including representatives of the NDA, a Data Custodian and representatives of the staff and trades unions, was involved in reviewing options between 2010 and 2011 and was instrumental in endorsing the NDA approach involving contracting with the HPA and a longer term aim of bringing together the UK radiation worker epidemiology research assets. Accordingly, in December 2011, NDA placed contracts with the HPA to stabilise, manage and develop the NDA radiation epidemiology and radiobiology programmes and associated research assets.

The current arrangement continues to support the NDA 2006 strategy in which we committed to support the collection and management of data and assets in addition to research programmes.

1.2.3 2011-2013 Status

It is noted that, as of April 2013 (and as a result of the Health and Social Care Act 2012), the functions of the HPA were assumed by Public Health England (PHE), a new executive agency of the Department of Health (DH). This change was anticipated and, as staff and contracts transferred from HPA to PHE, has not caused any disruption to the arrangements put in place to manage this topic area.
1.3 Case for Change

Although we undertook an options review with stakeholders within the NDA and the Governance Group prior to establishing the stabilisation stage, we considered it appropriate to undertake a wider review as we seek to confirm the NDA Strategy in this area and move to implement the next stages of the Strategy.

We seek, in particular, to consider the possibility for putting in place long-term national strategic arrangements that would allow NDA to realign its role within this area so that it is more in keeping with its mission.

1.4 Aspirational Outcomes

There are a number of outcomes that NDA would wish to see as a result of this strategic review:

- NDA would like its role in relation to this research topic re-aligned with its overall mission and specific needs in this area.
- NDA expect that national research assets should be protected for future use.
- NDA believe that a wider (national) strategic vision for this area may help to deliver longer term cost savings as well as research benefits and research efficiencies.

1.5 Scope and Boundaries

In keeping with our latest Strategy for R&D\(^2\), NDA must ensure that it conducts sufficient and appropriate research to support and technically underpin the delivery of its overall mission. The scope of this topic covers radiation epidemiology and radiobiology research in general and the specific research assets and associated research that now fall directly within the NDA estate. We aim to harmonise our research requirements in this area with those of other organisations to ensure a coherent and coordinated approach to enabling and supporting relevant research.

Our normal operating model of delivery through others means that we do not wish to directly manage either the research work or the research assets associated with this topic. We also do not consider ourselves best placed or equipped to directly manage either of these areas of work, as to do so effectively, we would need to recruit additional suitably qualified and experienced staff.

We consider that the current review, whilst not urgent, is important and is sufficiently well understood to propose acceptance of a preferred option by end of 2014.

1.6 Constraints

Because of the nature of this topic there are legal and ethical constraints associated with it and any strategy for this area must ensure that these are addressed. All research must be conducted and all research assets must be managed in a legal and
ethical manner. Beyond the legal and ethical constraints on this work, there are potentially less clearly definable moral issues that may need to be taken into account and addressing such issues is part of the remit of the Governance Group that oversees this work.

1.6.1 Legal

The epidemiological databases associated with this topic area contain personal information, therefore their operation is subject to the Data Protection Act (DPA) and the Caldicott Principles, which underlie the use of personally identifiable information within the health services.

The samples (taken from blood) and collected for specific radiobiological projects are regulated by the Human Tissue Authority (HTA).

1.6.2 Ethical

The current projects were established with appropriate ethical approval but new research projects would need the approval of appropriate governance groups and/or ethics committees.

It is unethical to maintain research assets without a clear strategy to use them for productive research, so any research strategy that seeks to preserve these assets should have a research programme associated with it.

There is an ethical obligation to conclude research, if at all possible, once it has been initiated and this means that there is an onus to ensure that any strategy selected for the delivery of research must be robust.

1.7 Risks

The principal risk associated with failure to conduct adequate research in this topic area is the failure to adequately understand the risks from radiation exposure and hence to be able to provide reassurance to stakeholders that these risks are acceptable. Decommissioning relies on the availability of a suitably skilled and qualified workforce and such workers need reassurance that the specific risks from the activities associated with the NDA mission have been adequately addressed.

The knowledge acquired from previous epidemiological and radiobiological work has demonstrated the applicability of internationally agreed dose limits (derived largely from work involving Japanese bomb survivors and medically exposed patients) to the protection of a UK nuclear workforce.

Perception of radiation risk is a major factor in relation to workforce, stakeholder and public acceptability of all nuclear operations including decommissioning. Inadequate understanding of risk could lead to inappropriate restrictions and protection constraints which would impact on our ability to undertake our core decommissioning work.
Data collected for internally exposed workers in the UK nuclear populations will be key to better understanding - and it is expected reassurances - of the impacts of such exposures. This is an area of significant interest to a company and workforce primarily concerned with decommissioning and clean-up.

Epidemiological studies of workers at sites within the NDA estate can provide valuable information about risk as well as specific reassurance - to the workforce, SLCs, the public, NDA and government - that risks within these workforces are being appropriately assessed and controlled. We are mindful of an ethical obligation to employees of legacy companies (such as BNFL and UKAEA) to ensure that work begun under such management is fully followed through to completion.

There is significant interest in radiation epidemiology and radiobiology research (e.g. EU programmes MELODI and DoReMi) and the NDA-owned databases are recognised as important research assets. Failure to appropriately protect the research assets developed by our legacy organisations could cause reputational damage to the NDA and UK, both at home and internationally.
2 Preferred Option

The objective of NDA’s Radiation Epidemiology and Radiobiology Research Strategy is to ensure that our assets are appropriately managed and that research relevant to our mission is carried out. A key question to be addressed is that of the long-term strategic role of NDA with regard to radiation epidemiology and radiobiology. To address this question we identified a number of potential strategic options in the Credible Options paper.

2.1 Options Considered

1. Close the programme and withdraw from these areas

This review provides an opportunity to consider whether there are still compelling reasons to continue with this activity into the future. If there are not, the strategy should obviously be to withdraw from the topic area. This option would mean closure of the programme and disposal of any assets (e.g. databases).

2. Close the programme but maintain watching brief

This review provides an opportunity to consider whether there are sufficient research resources available or research being carried out by other parties, such that NDA does not need to maintain its assets and carry out new research. If there is, the strategy should be to withdraw from active involvement but maintain an interest on the outcome of research in this area. This option would mean closure of the programme and disposal of any assets (e.g. databases).

3. Compete the programme through open tender with NDA maintaining overall management responsibility

Competition is central to our overall Strategy. We run competitions as part of our statutory duties to secure value for money, promote competition, promote best practice and meet our legal duties under the European Procurement Regulations and Energy Act 2004. NDA’s preferred method of operating, where the option exists, is therefore to openly compete contracts for delivery of specific projects. This option would allow both the programme and database to be maintained. NDA would continue to own any assets and provide overall strategic direction.

4. Devolve responsibility for management of the programme to one of our SLCs

Within larger packages of work, such as those to manage sites within the NDA estate, we can choose to devolve responsibility for the management and delivery of specific programmes. Responsibility for the oversight of radiation epidemiological and radiobiological research could be devolved back to the SLCs through our normal contractual arrangements with them. It is likely that any SLC would sub-contract the operation of the databases. This option would allow both the programme and database to be maintained. NDA would continue to own any assets and provide overall strategic direction.
5. **Further develop a strategic relationship with PHE (formerly the HPA) with the long-term aim of restructuring the ownership and management of the assets**

We recognise that other government bodies have an interest in this topic area and some have considerably more experience within it than NDA and so may be better placed to take a wider strategic view and to take this work forward. In particular PHE (Public Health England) has internationally recognised expertise in this area and already manages on behalf of the Department of Health national research assets including the UK-wide radiation worker epidemiology database, the National Registry for Radiation Workers (NRRW). HPA, whose functions were assumed by PHE as a result of the Health and Social Care Act 2012, was also highlighted in the Nuclear Industrial Strategy\[^4\] as having an important role on behalf of Government in improving the public understanding of radiation and how it is used in society and managed within the nuclear industry. PHE is currently managing the research and research assets associated with our current programme and has confirmed interest in doing so in the longer term. This strategic relationship could potentially result in the following:

- PHE taking greater leadership in the strategic direction of the programme with NDA focusing solely on its legal responsibilities (e.g. Data Protection Act) and Energy Act requirements (e.g. commissioning research relevant to our decommissioning mission);
- Combined governance (ex-BNFL, ex-UKAEA and NRRW); and
- Transfer of assets (e.g. databases) and funding from NDA to PHE (via their sponsoring departments) so as to better reflect the overall NDA strategic objectives.

Such changes would need approval by the relevant stakeholders and governance groups.

### 2.2 Identification and Application of Initial Screening Criteria

To confirm our preferred strategy for this topic we evaluated the potential strategic options against a range of criteria identified using the NDA’s Value Framework as a basis.

The criteria that we arrived at were derived from our strategic objective and aspirational outcomes for this strategy and also reflected the constraints that are placed on this topic area. They sought to answer the following questions:

- **Does the strategy align with Government’s overall Nuclear Industrial Strategy and specifically the identified organisational roles with respect to the public understanding of radiation?**
- **Does the strategy align with our overall strategy for delivery of R&D?**
- **Will the strategy achieve best value for money?** (Value Framework: Cost)
• Will the strategy protect the research assets currently within the NDA estate?
• Is the strategy deliverable and sustainable over the long term?
• Will the implementation of the strategy allow us to meet all legal and ethical requirements? (Value Framework: Security)
• How independent is the research from the nuclear industry?
• Will the strategy deliver the research we actually need? (Value Framework: Safety)
• Will the strategy align with NDA’s role as the strategic body responsible for decommissioning the UK’s nuclear legacy?

Our initial evaluation of the potential strategic options against these criteria, employing a ‘Traffic light’ approach, is presented in Table 1 and 2 (RED = Negative impact, AMBER = Neutral impact, GREEN = Positive impact).
<table>
<thead>
<tr>
<th>Option 1</th>
<th>Option 2</th>
<th>Option 3</th>
<th>Option 4</th>
<th>Option 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Withdraw from this area</strong></td>
<td><strong>Maintain watching brief</strong></td>
<td><strong>Compete management programme</strong></td>
<td><strong>Devolve management responsibility to the SLCs</strong></td>
<td><strong>Further our strategic relationship with PHE</strong></td>
</tr>
<tr>
<td>Aligns with Government’s Nuclear Industrial Strategy and identified organisational roles</td>
<td>NDA estate has a significant workforce of radiation workers and will need to engage at some level</td>
<td>NDA will need to coordinate its involvement through the Nuclear Industry Council</td>
<td>SLC will need to coordinate its involvement through the NDA and Nuclear Industry Council</td>
<td>Government with PHE and the Nuclear Industry Council will work with universities, research institutes and others on programmes that improve understanding of radiation and how it is used in society and managed within the nuclear industry.</td>
</tr>
<tr>
<td>Aligns with NDA’s R&amp;D strategy</td>
<td>NDA estate has a significant workforce of radiation workers and will need to engage at some level</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Value for money</td>
<td>Limited costs to close out and for continuing surveillance.</td>
<td>No cost saving.</td>
<td>No cost saving.</td>
<td>Potential cost saving (to government) through integrated national strategy.</td>
</tr>
<tr>
<td>Protection of research assets</td>
<td>Assets would have to be destroyed.</td>
<td>Unknown, previous experience has cast doubt on the robustness of small research groups.</td>
<td>Unknown, previous experience has cast doubt on the robustness of small research groups.</td>
<td>Extensive experience in managing and protecting such research assets.</td>
</tr>
</tbody>
</table>

Table 1: Initial Assessment of Strategic Options
### Table 2: Initial Assessment of Strategic Options - Continued

<table>
<thead>
<tr>
<th>Epidemiology and Radiobiology Options</th>
<th>Option 1</th>
<th>Option 2</th>
<th>Option 3</th>
<th>Option 4</th>
<th>Option 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Option 1</strong></td>
<td>Withdraw from this area</td>
<td>Maintain watching brief</td>
<td>Compete management programme</td>
<td>Devolve management responsibility to the SLCs</td>
<td>Further our strategic relationship with PHE</td>
</tr>
<tr>
<td>Deliverable and sustainable</td>
<td>Closure relatively straightforward.</td>
<td>Closure relatively straightforward.</td>
<td>Limited competition available.</td>
<td>Limited alignment with existing SLC programmes.</td>
<td>Need to further develop strategic relationship.</td>
</tr>
<tr>
<td>Meets legal and ethical requirements</td>
<td>Failure to finalise partially completed research could be considered unethical.</td>
<td>Failure to finalise partially completed research could be considered unethical.</td>
<td>Ensured through selection of suitable contractor.</td>
<td>Ensured through selection of suitable SLC (and potentially sub-contractor).</td>
<td>PHE already operates within these legal and ethical frameworks.</td>
</tr>
<tr>
<td>Independence of research from nuclear industry</td>
<td>NDA not involved in directing research.</td>
<td>NDA not involved in directing research.</td>
<td>NDA involved in research via contractor.</td>
<td>NDA and an SLC involved in research.</td>
<td>Greater independence as PHE take larger role.</td>
</tr>
<tr>
<td>Ability to deliver relevant research</td>
<td>No research possible. The NDA-PHE Epidemiology Governance Group strongly believes that research will be required.</td>
<td>No research possible. The NDA-PHE Epidemiology Governance Group strongly believes that research will be required.</td>
<td>Unknown, there are a limited number of qualified research groups.</td>
<td>Unknown, there are a limited number of qualified research groups and there may be difficulties associated with site based interests.</td>
<td>Internationally recognised experience and ability in this area.</td>
</tr>
<tr>
<td>Aligns with NDA role as a strategic body</td>
<td>NDA estate has a significant workforce of radiation workers and will need to engage at some level.</td>
<td>NDA would have limited ability to align future research with its needs.</td>
<td>NDA would still need to retain overall responsibility.</td>
<td>NDA likely to have to retain a responsibility to hold together the NDA-wide interest over the specific SLC interest.</td>
<td>Yes.</td>
</tr>
</tbody>
</table>
2.3 Stakeholder Views

We have received comments on the Credible Options paper from the epidemiology and radiobiology research Governance Group and six other stakeholders/stakeholder groups.

It was clear that there continues to be considerable stakeholder interest in this topic.

There was also clear support for the need to maintain and make use of the research assets built up over decades and there was general endorsement of the NDA’s efforts and commitment to preserving and supporting the programme area.

While the NDA was also recognised as a key stakeholder through their position as an employer (directly or indirectly) of significant numbers of staff in the nuclear industry, the potential conflict of interest for NDA as a research lead was also accepted.

A comment on the industry position, should changes to dose limits be proposed, supported the importance of directly relevant research.

There were some comments on the assessment process and criteria. Most stakeholders were supportive of the process and criteria used, some proposed minor modifications. However, those stakeholders suggesting modifications recognised that these proposed changes would be very unlikely to have a material impact on the outcome of this assessment and were supportive of the original outcome.

Some stakeholders suggested other bodies that could potentially be involved in funding, managing and/or delivering this work. NDA have not, however, received any indication from these bodies that they would wish to be involved and nor have those bodies contributed to the options consultation. In contrast, PHE have reaffirmed their commitment to this work and stakeholder consensus was that they were the most suitable body to take it forward.

While there was some limited support for Options 3 and 4 as credible fallback options, there was no support for Options 1 and 2, with some stakeholders being strongly opposed to them being included or considered further. All stakeholders were clearly supportive of Option 5 being the preferred option to take forward.
2.4 Strategic Options Review

The Strategic Options for radiation epidemiology and radiobiology have been reviewed in the light of stakeholder comments and the initial screening criteria. Following this review we have been able to categorise the potential strategic options into one of the three categories given in Table 3 and the outcome is presented in Table 4.

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred</td>
<td>Likely to be deliverable, would meet the key objectives as defined and assessed to offer the best strategic option.</td>
</tr>
<tr>
<td>Contingent</td>
<td>Potentially deliverable, would meet some key objectives and warrants further development if the Preferred option proves to be undeliverable.</td>
</tr>
<tr>
<td>Rejected</td>
<td>Many apparent shortcomings, will not be developed further.</td>
</tr>
</tbody>
</table>

Table 3: Strategic Option Categories
Table 4: Strategic Option Review

<table>
<thead>
<tr>
<th>Option</th>
<th>Category</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Option 1</strong></td>
<td>Reject</td>
<td>Fails to meet many key criteria and has no stakeholder support.</td>
</tr>
<tr>
<td>Withdraw from this area</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Option 2</strong></td>
<td>Reject</td>
<td>Fails to meet key criteria and has no stakeholder support.</td>
</tr>
<tr>
<td>Maintain watching brief</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Option 3</strong></td>
<td>Contingent</td>
<td>Has potential to meet some key criteria; has limited stakeholder support.</td>
</tr>
<tr>
<td>Compete management programme</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Option 4</strong></td>
<td>Contingent</td>
<td>Has potential to meet some key criteria; has limited stakeholder support.</td>
</tr>
<tr>
<td>Devolve management responsibility to the SLCs</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Option 5</strong></td>
<td>Preferred</td>
<td>Meets or has the potential to meet, all key criteria and has clear stakeholder support.</td>
</tr>
<tr>
<td>Further our strategic relationship with PHE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.5 Preferred Option

The outcome of the strategic option review shows that Option 5 - ‘Further develop a strategic relationship with PHE’ is clearly the Preferred option to take forward.

2.6 Strategic Options Diagram (SOD)

The Strategic Options Diagram for radiation epidemiology and radiobiology has been updated to reflect the preferred option and is presented in Appendix A.
2.7 Stakeholder Engagement Plan

In identifying the potential strategic options and selection criteria, we have engaged with PHE, Data Custodians, union representatives and internal NDA stakeholders. The resulting Credible Options paper\[1\] was published on our website and all interested parties were invited to comment on it.

We will continue to engage with stakeholders as we move forward with the preferred option.

The importance of external stakeholder support, particularly for key stakeholder groups such as the workforce and their representatives, has been identified as being critical to the success of the proposed strategy.

2.8 Communications Plan

We have presented our Radiation Epidemiology and Radiobiology Research Credible Options paper\[1\] at the NDA-PHE Epidemiology Governance Group, NDA Strategy Delivery and Implementation Group (SDIG) and published it via our website for comment.

We will share this Preferred Option paper with the Governance Group and the SDIG and publish it via our website.
3 Summary

3.1 Summary of Our Assessment

Having reviewed the potential strategic options, including taking into account the views of other stakeholders, we have concluded that Option 5 - ‘Further develop a strategic relationship with PHE’ is the preferred option to take forward.

3.2 Way Forward

NDA will further develop its strategic relationship with PHE whilst ensuring that our assets are appropriately managed and that research relevant to our mission is carried out. We will also investigate further the possibility of restructuring the ownership and management of the assets. A key part of this will be to continue to understand the views of stakeholders as we move forward with this strategy. Legal, ethical and financial implications of any restructuring will need to be considered. We will provide regular updates on the implementation of this strategy and provide the opportunity for stakeholders to express their views on any proposed restructuring.
References


2 NDA, *Research and Development – Approve Strategy (Gate C)*, March 2011.


Appendix A – Radiation Epidemiology & Radiobiology
Strategic Options Diagram

Radiation Epidemiology & Radiobiology
To define the long-term strategic role of NDA with regard to this topic

Option 1
Withdraw from this area

Option 2
Maintain watching brief

Option 3
Compete programme

Option 4
Transfer responsibility to an SLC

Option 5
Further our strategic relationship with PHE

Preferred Option

Greater leadership by PHE; NDA maintain legal responsibilities

Combine governance with NRRW

Transfer assets & funding